

## HB 2390 STAFF MEASURE SUMMARY

### House Committee On Health Care

---

**Prepared By:** Brian Nieuburt, LPRO Analyst

**Meeting Dates:** 2/23

---

#### **WHAT THE MEASURE DOES:**

Requires health benefit plans to cover treatment for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome, including but not limited to intravenous immunoglobulin therapy and plasmapheresis. Specifies permitted coding for billing and diagnosis.

*REVENUE: May have revenue impact, but no statement yet issued.*

*FISCAL: May have fiscal impact, but no statement yet issued.*

#### **ISSUES DISCUSSED:**

#### **EFFECT OF AMENDMENT:**

No amendment.

#### **BACKGROUND:**

The National Institute of Mental Health defines pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) as pediatric disorders that often appear in childhood from age 3 to 12. The diagnosis of PANDAS is a clinical diagnosis based on diagnostic criteria by a health care professional. Symptoms may include motor or vocal tics, obsessions, compulsions, or a combination of these. PANDAS is a diagnosis given to children who experience a sudden and dramatic onset or worsening of Obsessive Compulsive Disorder (OCD) and/or tic disorders following a streptococcal infection. Children diagnosed with PANDAS may also experience anxiety, inattention, trouble sleeping, and changes in motor skills, among other symptoms. A distinction between PANDAS and PANS is that children diagnosed with PANS have no association with an underlying streptococcal infection. Both PANDAS and PANS are described in the medical literature as episodic conditions, and individuals diagnosed with PANDAS or PANS are expected to experience periods of symptom reduction or remission with the disorders. In 2019, the Oregon legislature passed House Bill 2510 creating PANDAS/PANS Awareness Day on October 9 of each year.

House Bill 2390 requires health benefit plans to cover treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS).